- Home
- DOMH vs EVOK Comparison
DOMH vs EVOK Comparison
Compare DOMH & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- EVOK
- Stock Information
- Founded
- DOMH 1967
- EVOK 2007
- Country
- DOMH United States
- EVOK United States
- Employees
- DOMH N/A
- EVOK N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- EVOK Health Care
- Exchange
- DOMH Nasdaq
- EVOK Nasdaq
- Market Cap
- DOMH 74.9M
- EVOK 7.1M
- IPO Year
- DOMH N/A
- EVOK 2013
- Fundamental
- Price
- DOMH $10.10
- EVOK $5.06
- Analyst Decision
- DOMH
- EVOK
- Analyst Count
- DOMH 0
- EVOK 0
- Target Price
- DOMH N/A
- EVOK N/A
- AVG Volume (30 Days)
- DOMH 4.2M
- EVOK 8.4K
- Earning Date
- DOMH 03-31-2025
- EVOK 03-13-2025
- Dividend Yield
- DOMH N/A
- EVOK N/A
- EPS Growth
- DOMH N/A
- EVOK N/A
- EPS
- DOMH N/A
- EVOK N/A
- Revenue
- DOMH $12,589,000.00
- EVOK $8,617,036.00
- Revenue This Year
- DOMH N/A
- EVOK $97.35
- Revenue Next Year
- DOMH N/A
- EVOK $99.52
- P/E Ratio
- DOMH N/A
- EVOK N/A
- Revenue Growth
- DOMH 1117.50
- EVOK 100.35
- 52 Week Low
- DOMH $0.83
- EVOK $3.54
- 52 Week High
- DOMH $13.58
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- DOMH 68.93
- EVOK 61.52
- Support Level
- DOMH $8.25
- EVOK $4.68
- Resistance Level
- DOMH $13.58
- EVOK $5.40
- Average True Range (ATR)
- DOMH 1.89
- EVOK 0.34
- MACD
- DOMH 0.74
- EVOK 0.07
- Stochastic Oscillator
- DOMH 65.64
- EVOK 85.98
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.